Genetic polymorphisms in superoxide-producing NAD(P)H oxidase have been linked to cardiovascular diseases including anthracycline-induced cardiotoxicity. We quantified NAD(P)H oxidase activity in granulocytes of 81 healthy Caucasian volunteers (in addition, 51 in an independent confirmatory study) by chemiluminescence using the luminol analogue L-012. Expression of CYBA, NCF4 and RAC2 coding for NAD(P)H oxidase subunits was measured in whole blood cells in 59 study participants by realtime PCR. Of the five variants investigated (À930A4G, 242C4T, 640A4G in CYBA and the recently reported À368G4A in NCF4 and 7508T4A in RAC2), only CYBA 640A4G was consistently associated with superoxide production (640GG carriers 28% less than AA individuals, P ¼ 0.05 in each cohort, P ¼ 0.005 in combined analysis). RAC2 7508T4A was related to higher expression of RAC2 (P ¼ 0.02) and NCF4 (P ¼ 0.04). In summary, CYBA 640A4G rather than 242C4T was associated with reduced activity. The quantitatively moderate effect and the high intra-individual variability should be considered for further study design.
Introduction
Reactive oxygen species (ROS) play a pivotal role in health and disease. ROS are used by phagocytes to kill bacteria and other invaders.
1,2 But function of ROS is much beyond as they serve also as cellular messengers involved in a variety of biological processes including tissue growth, cell differentiation and proliferation, 3,4 apoptosis 5, 6 and regulation of blood vessel tone. 7 Overproduction of ROS has been associated with diverse diseases including neurodegenerative disorders, 8 cancer 9, 10 or cardiovascular impairments. 11 Starting from superoxide anion, other ROS like hydrogen peroxide, hydroxyl radicals or hypochloric acid are formed by multi-step reactions. NAD(P)H oxidase is one of the major sources for superoxide generation. It was first found to be highly expressed in phagocytic cells, but is now believed to be present in almost all cell types, however, at much lower amounts. 12 Superoxide formation by NAD(P)H oxidase is according to the reaction: NAD(P)H þ 2 O 2 -NAD(P)
KÀ
. The enzyme NAD(P)H oxidase is capable of catalysing two superoxide anions from two molecules of oxygen and one NAD(P)H molecule. Alternatively, the enzyme may also utilize NADH as electron donor.
Composition of NAD(P)H oxidases vary among cell types, but some features are common. Two subunits are membrane-anchored, a big catalytic subunit (termed gp91phox in phagocytes, gene name CYBB) and a smaller adjacent subunit (termed p22phox in phagocytes, CYBA). The latter is identical in all cells whereas at least seven homologues of the big catalytic subunit have been identified. 13, 14 Four cytosolic proteins are known to affect NAD(P)H oxidase activity by interacting with the membrane-associated subunits upon stimulation. 12 In neutrophilic granulocytes, these are p67phox (NCF2), p47phox (NCF1), p40phox (NCF4) and the small GTP-binding protein rac2 (RAC2). The oxidase activity can be stimulated potently by phorbol 12-myristate 13-acetate (PMA) leading to phosphorylation of the NAD(P)H oxidase subunit p47phox via protein kinase C 15, 16 resulting in subunit assembly. Several clinical-epidemiological studies have linked three single nucleotide polymorphisms (SNPs) of the CYBA gene with various outcomes, mainly cardiovascular diseases. The À930A4G polymorphism in the 5 0 region of CYBA was reported to be associated with hypertension and higher promoter activity 17 as well as with an increased p22phox expression in hypertensive individuals. 18 The first study addressing the functionality of the His72Tyr amino acid substitution (242C4T) in p22phox revealed a reduced superoxide production both basal and stimulated in human blood vessel cells carrying the 242T allele. 19 This finding was confirmed in neutrophilic granulocytes albeit only under stimulated conditions. 20 In marked contrast, another group observed significantly higher superoxide production in carriers of the 242T allele. 21 Gardemann et al. 22 delineated an association of the 640A4G polymorphism in the 3 0 UTR of CYBA with cardiovascular arterial disease, in particular in hypertensives. This SNP might modify processing or stability of p22phox mRNA. However, a functional impact of this SNP on NAD(P)H oxidase activity could not be proven. 20 In summary, polymorphisms in NAD(P)H oxidase may be highly relevant for various diseases but the present functional and clinical-epidemiological data are inconclusive.
Recently, we screened about 100 candidate genes for anthracycline-induced cardiotoxicity and identified three SNPs in genes coding for NAD(P)H oxidase subunits as potential risk factors for this life-threatening adverse event;
23 the 242C4T polymorphism of CYBA, an intronic variant of RAC2 (7508T4A) and an SNP in the promoter region of NCF4 (À368A4G). The functional impact of the variants in NCF4 and RAC2 has not been analysed to our knowledge.
This study represents a random sample of a healthy Caucasian population of German origin with 81 volunteers participating. We set to investigate whether the two variants (RAC2 7508T4A and NCF4 À368G4A) and the three in CYBA (À930A4G, 242C4T and 640A4G) impact enzyme activity and gene expression. We measured enzymatic activity at basal levels and upon stimulation with either PMA or zymosan. Moreover, as NAD(P)H oxidase activity is much dependent on rapidly changing environmental factors (for example, contact with pathogens, nutrition), assessment of intra-individual variability was estimated performing measurements at two different occasions in 54 of the participating individuals.
Results
In both independent studies (the first with n ¼ 81 healthy volunteers and the second confirmatory with n ¼ 51), all genotype frequencies were in Hardy-Weinberg equilibrium ( Table 1 ). The three CYBA polymorphisms were not in linkage disequilibrium (LD) (r 2 o0.05) and therefore, no haplotypes were calculated. NCF4 and RAC2 are located on chromosome 22 with a distance of 350 000 bp, but there was no LD between these SNPs.
Basal mRNA expression of the genes CYBA, NCF4 and RAC2 was measured in whole blood leukocytes from 59 of the study participants. Distribution of all the three gene transcripts was skewed to the left. Statistically significant pair-wise correlations (each n ¼ 59) were observed with Spearman's rank correlation analysis between CYBA and NCF4 (coefficient r ¼ 0.65, Po0.001), CYBA and RAC2 (r ¼ 0.56, Po0.001) and NCF4 and RAC2 (r ¼ 0.65, Po0.001) indicating significant coregulation of these genes. For 46 persons, whole blood leukocyte RNA was available at two different study days with an interval of at least 1 week. Repeated quantification revealed inter-individual variability Figure 1a ) and NCF4 (P ¼ 0.04, Figure 1b ). Visual inspection also suggested an impact on CYBA expression but that was not statistically significant (P ¼ 0.11, Figure 1c ). RAC2 7508AA carriers exhibited on average 1.5-fold more RAC2 transcripts than TT individuals. Expression of TATA box-binding protein (TBP) serving as a normalization gene was not affected by this SNP in RAC2 (data not shown). None of the other four variants investigated was related to expression of CYBA, RAC2 and NCF4. NAD(P)H oxidase activity was measured in granulocytes after stimulation with PMA or zymosan with L-012 as reagent. Fifty-four of the 81 subjects studied were analysed twice on two different occasions. We analysed both maximum reaction velocity (v max ) of reactive species formation and its integrated amount over a time period of 60 min (AUC 60 ). Both data analysis parameters were tightly related (Spearman's r ¼ 0.93 upon PMA and r ¼ 0.95 upon zymosan Figure 1 Effect of the RAC2 7508T4A polymorphism on expression of RAC2 (a), NCF4 (b) and CYBA (c) in 59 study participants from whom total blood RNA was available. Non-parametric testing was performed with Jonckheere-Terpstra's trend test (considering effects between the three genotypic groups in order of the number of variant alleles). All transcript numbers are normalized to TBP. CYBA and NCF4 were absolutely quantified using standard clones, RAC2 expression is indicated relatively to the lowest value in the measurement series. Boxes depict first and third quartiles, with the median value indicated as a bold line within the box. Thin lines mark samples with the lowest and highest values, with the exception of outliers, which are drawn as circles (1.5-3 times the interquartile range below the first quartile or above the third quartile) or asteriks (more than three times outside the interquartile range). TBP, TATA box-binding protein.
stimulation). PMA-and zymosan-stimulated ROS formation correlated well with one another (r ¼ 0.76 and r ¼ 0.80). There was no correlation of ROS formation between stimulated and unstimulated cells (r ¼ 0.1). Frequency distributions of the data obtained with either PMA or zymosan stimulation are illustrated in Figure 2 . Correlation analysis between expression of CYBA, NCF4 or RAC2 and activity was not appropriate since expression analysed in RNA from whole blood is predominantly that of mononuclear cells and not of granulocytes.
Thirty-eight and 22% of ROS production upon PMA and zymosan activation was attributable to inter-personal variation suggesting that less-specific stimulation is less related to personally constant parameters like the genotypic composition.
NAD(P)H oxidase activity was not statistically significantly different between the three CYBA 242 genotypes (CC, CT and TT), either in the first study or in the second confirmatory study (Figures 3a and b) .
Only the CYBA 640A4G polymorphism was reproducibly associated with increased NAD(P)H oxidase activity. In the first study, activity was affected by this variant stimulated either with PMA (P ¼ 0.05, Figure 4a ) or with zymosan (P ¼ 0.03, each considering a codominant mode of inheritance using the non-parametric Jonckheere-Terpstra trend test). This effect was confirmed (P ¼ 0.04) in the second Figure 2 Histograms of superoxide production in samples from the first study. Dense data points were recorded to determine maximum formation rate (v max ) within 60 min upon stimulation at 371C ((a) stimulated with PMA ad 10 ng/ml, (b) with zymosan ad 400 mg/ml). The figures illustrate data from 81 persons. In case of measurements at two different days (n ¼ 54) the means were taken. With both stimuli, an approximately normal distribution was observed. PMA, phorbol 12-myristate 13-acetate. study group (Figure 4b) . Therein, as a more-specific parameter for the flavine enzyme NAD(P)H oxidase, the diphenylene iodonium chloride (DPI)-inhibitable proportion of superoxide production was also determined and was related to CYBA 640A4G in the same manner (P ¼ 0.02). A linear regression analysis was applied for combined analysis of both studies with PMA stimulation. Since there were 40% women in the second study, adjustment for gender was performed and turned out not to have any impact. Thereby, compared to the single studies, an increased statistical significance was obtained for CYBA 640A4G (P ¼ 0.005), which remained significant after conservative Bonferroni adjustment for multiple testing with five polymorphisms. Basal NAD(P)H oxidase activity was not related to the CYBA 640A4G SNP.
The CYBA À930A4G SNP located in the promoter region of this gene did not show any effect on ROS formation either upon administration of any of the applied stimuli or in unstimulated granulocytes. In view of both studies, no significant impact of the polymorphism À368G4A, in the promoter region of NCF4 on NAD(P)H oxidase activity, was seen either on the basal level or stimulated. L-012-derived chemiluminescence neither in unstimulated granulocytes nor upon treatment with PMA or zymosan was dependent on the polymorphism RAC2 7508T4A.
The
Discussion
There was substantial inter-individual variability in the mRNA expression of the NAD(P)H oxidase subunits and in NAD(P)H oxidase activity among otherwise comparable healthy subjects. Transcript numbers of CYBA, NCF4 and RAC2 varied 7-to 11-fold among subjects. Repeated measurement analysis revealed a high proportion of interindividual variability in NAD(P)H oxidase gene expression which was between 37 and 77% depending on the subunit.
Enzyme activity at single-day measurements varied 7.0-fold after PMA and 6.3-fold after zymosan stimulation. When taking individual mean values of two separate study days, the corresponding relations were 2.9-and 2.6-fold, respectively. Activity in ROS formation was individually less constant than NAD(P)H oxidase expression but again there was substantial inter-subject variability. Such data suggest a strong impact of individually constant features such as the genetic make-up. 24 However, this conclusion should be confirmed and clarified in detail in a twin study. The strong correlation of induced activity with the two potent stimuli, PMA and zymosan (r ¼ 0.80), indicates that the underlying mechanisms resemble with one another and if a polymorphism is functional it should be functional under both conditions. We analysed five polymorphisms, three variants which have recently been associated with anthracyclineinduced cardiotoxicity 23 and, in addition, the other two NAD(P)H oxidase variants frequently discussed in relation to several clinical phenotypes. 17, 18, 22 The most extensively studied NAD(P)H oxidase polymorphism is the 242C4T variant of CYBA causing His4Tyr substitution at position 72. We could not demonstrate a consistent impact of this variant on enzyme activity. Only when restricting analysis to repeated measurements at two different study days (a subgroup of n ¼ 54 from the first study), we detected a similar effect as Wyche et al., 20 who reported about 30% less activity for the TT-allele status. In contrast, another group has reported an increased superoxide formation for the 242T allele. 21 Thus, our data with TT carriers showing a slight tendency to a lower activity in the first and towards a higher in the second study are in line with the so far conflicting reports. This can be explained by the quantitatively low effect with respect to the obviously high intra-individual variability.
However, we observed a significantly decreased ROS formation with increasing numbers of 640G variant alleles. Carriers of the GG genotype produced about 30% less ROS than wild-type carriers and a gene dose effect (codominant mode of inheritance) was seen. These results were reproducible in both study groups regardless of the applied stimulus. A functional significance of the CYBA 640A4G SNP might be supported by a recent report 25 in which carriers of the wild-type A allele responded better to exerciseinduced reduction in plasma thiobarbituric acid reactive substances, an indicator of ROS-mediated lipid oxidation. In our analyses, CYBA 640G4A was not implicated in transcript numbers of CYBA. Thus, an implication in the post-transcriptional regulation of the NAD(P)H oxidase activity such as effects on the translation efficiency or protein trafficking could be suggested as a mechanism to explain the observed dependence. In a Japanese population, LD has been described between the polymorphisms 242C4T and 640A4G. 26 In our Caucasian population, we did not observe LD between the three investigated CYBA variants and hence haplotype analysis was not suitable. Nevertheless, these inter-ethnic differences in genetic linkage may be one reason for discrepant results between Caucasian and Asian populations.
The À930A4G variant in the promoter region of CYBA has been previously proposed to be a risk factor for hypertension 17 and might be a determinant of NAD(P)H oxidase expression and activity in hypertensive patients. 18 In granulocytes of healthy subjects, we did not see any influence on gene expression or activity in accordance to published data. 20 Two other NAD(P)H oxidase polymorphisms previously associated with anthracycline-induced cardiotoxicity 23 have not yet been functionally characterized; one in the promoter region of the NCF4 gene coding for the regulatory cytosolic subunit p40phox and one intronic polymorphism in the RAC2 gene coding for the small GTP-binding protein rac2. The promoter variant À368G4A of the NCF4 gene was related to the risk of chronic heart failure following anthracycline administration. Neither expression analyses nor analyses of enzymatic activity revealed a statistically significant functional effect of this polymorphism. Furthermore, we performed reporter gene analyses of the 2 kb NCF4 promoter fragment. No apparent differences caused by the À368G4A variant could be suggested (data not shown).
Until now, there are no data on the RAC2 7508T4A polymorphism besides the reported association with early signs of cardiotoxicity 23 whereas the AA genotype configuration was significantly associated with cardiotoxicity.
Here, we could demonstrate (Figures 1a and b) that the variant allele was associated with higher mRNA expression not only of its gene RAC2, but also of another gene, NCF4 (about 1.5-fold). Very recently, we found that this variant also affects expression of RAC2, NCF4 and CYBA ex vivo in peripheral blood mononuclear cells cultured for 24 h (data not published). In those experiments, cells harbouring the RAC2 7508A variant allele exhibited higher interleukin 2-induced expression of these three genes in a similar manner as was seen in whole blood (Figure 1) . However, this variant was not related to increased basal expression of these three genes as was observed in specimens drawn directly from whole blood. Therefore, these polymorphisms might modulate expression depending on the experimental conditions and cytokines present in whole blood which have been washed out by cell isolation might impact the effect of this SNP. The substantial correlation of RAC2, NCF4 and CYBA transcript numbers suggests an association with common upstream regulators. It is known that the haematopoiesisassociated factor-1 (containing PU.1) binds to and regulates several NAD(P)H oxidase subunits including p40phox. 27 Recently, nuclear factor-kB (NF-kB) has been demonstrated not only to be a downstream target of ROS, but also is an upstream regulator of NAD(P)H oxidase genes when cells are stimulated. 28 This supports the hypothesis of a positive feedback loop boosting ROS generation upon stimulation wherein NF-kB and other factors might play a pivotal role.
In conclusion, we could demonstrate a large extent in variability of NAD(P)H oxidase activity within subjects. A dependence on the CYBA 640A4G polymorphism was statistically significant and reproducibly observed. In addition, an intronic variant in RAC2 was related to mRNA transcripts of this gene and of another NAD(P)H oxidase component, NCF4. Comparative expression analyses in healthy volunteers and patients suffering from various diseases in which NAD(P)H oxidase is implicated could further elucidate the so far conflicting reports and help to understand better the condition in which a specific variant is relevant.
Materials and methods

Subjects
In total, 86 healthy volunteers participated in the first study. Four women were excluded from statistical analyses since they were too few for adjustment for a potential gender confounding effect. One man exhibited pathological WBC count and was therefore excluded from further analyses. All other subjects were healthy at the time of blood sampling as verified by a brief clinical examination, a questionnaire and a differential WBC count. Seventy-four participants were current nonsmokers. Four individuals were self-described smokers (one mild, two intermediate and one heavy smoker) and for four others the smoking status was not noted. Mean age was 30 ranging from 18 to 54. For phenotypic correlations as well as phenotypic-genotypic associations, all available measurements (activity n ¼ 81, RNA for expression analysis from n ¼ 59) were considered. From the 22 subjects who participated as donors for the local blood bank, RNA samples were not available. Intra-versus inter-individual variability was analysed in a subgroup of 54 persons from whom we could draw two blood samples on two separate study days at least 2 weeks apart.
In addition, we conducted a second independent confirmatory study comprising 51 healthy Caucasian volunteers of both gender (30 men). Both studies were approved by the ethics committee of the Medical Faculty of the GeorgAugust-University Göttingen. All participants have given their written informed consent.
Blood sampling and cell preparation Blood for isolation of granulocytes (predominantly neutrophilic) was drawn from the forearm vein into heparinized tubes (Li-heparin) . Ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood drawn at the same time was used for blood cell counts and for isolation of genomic DNA. Granulocytes were isolated from whole blood within 1 h after blood sampling using Polymorphprep centrifugation (Nycomed, Oslo, Norway) as described by the manufacturer. Isolated granulocytes were stained using Tuerk's solution (Merck, Darmstadt, Germany) and counted independently by two persons. The granulocytes were adjusted to a concentration of 2500 cells/ml in RPM1 medium containing 10% fetal calf serum and 1% antibiotic solution consisting of penicillin and streptomycin (all components from Invitrogen, Karlsruhe, Germany).
Superoxide measurement ROS production was assayed by L-012-derived chemiluminescence. 29, 30 Briefly, 5 Â 10 4 granulocytes were added to 200 ml phosphate-buffered saline supplemented with 5% glucose and containing 100 mM L-012 (Wako Chemicals, Osaka, Japan). The cells were stimulated either with PMA (10 ng/ml) or with opsonized zymosan A (400 mg/ml), which is further termed 'zymosan'. It was opsonized by boiling in 0.9% sodium chloride followed by incubation with a polyvalent human serum as described previously. 31 The reaction mixture was prepared on ice and the measurement was started by incubation at 371C using TECAN Ultra microplate reader (TECAN, Crailsheim, Germany). NAD(P)H oxidase measurements were performed in triplicates and recorded for 90 min. Maximum ROS production rate was observed within 60 min upon stimulation (usually 10-20 min after the reaction start). Since PMA and zymosan effects correlated strongly between the subjects, only PMA was used for stimulation in the second study in which also the DPI (10 mM)-inhibitable superoxide production was determined.
DNA polymorphism analyses
Genomic DNA was isolated from whole blood (EDTA) using EZ1 DNA Blood 350 ml Kit (Qiagen, Hilden, Germany) on a BioRobot EZ 1 system (Qiagen). The polymorphisms were analysed using commercially available TaqMan assays from Applied Biosystems (ABI, Lincoln, CA, USA) on a 7900 HT Sequence Detection System (ABI); CYBA 242C4T (His72Tyr, rs4673, customized ABI assay), CYBA 640A4G (rs1049255, ABI assay ID: C_7516913_10), NCF4 À368G4A (rs1883112, C_11521119_1) and RAC2 7508T4A (rs13058338, C_11744093_1). As an additional method for verification, genotyping by PCR-RFLP was carried out for CYBA variant 242C4T as described previously. 32 The CYBA variant À930A4G (rs9932581) was genotyped by BbvI digestion after PCR amplification with forward primer: 5 0 -ACCTG AGCCAATGTGGGGTTTGAGG-3 0 and reverse primer: 5 0 -TGCCCACGGCGCTTCTGCTGAGAC-3 0 . A minimum of 30% of the samples were analysed in duplicate or alternative methods (CYBA 242C4T) yielding identical genotypes.
RNA analyses
Gene expression of CYBA, NCF4 and RAC2 was determined in whole blood, that is from all RNA-containing peripheral blood cells to determine basal expression status. Therefore, venous blood was directly drawn into an RNA collection tube (PAXgene Blood RNA Tubes, Becton Dickinson, Heidelberg, Germany). Preparation of RNA was performed with PAXgene Blood RNA Kit (Qiagen) according to the manufacturer's instructions. After photometric quantification, transcription of 1 mg total RNA to cDNA was performed (421C for 60 min) using Superscript reverse transcriptase (Invitrogen) and random hexanucleotides (Roche, Mannheim, Germany) as primers. All expression measurements were carried out in duplicates by quantitative real-time PCR using TaqMan gene expression assays from Applied Biosystems (ID: Hs00164370_m1 for CYBA, Hs00241129_m1 for NCF4 and Hs00427439 for RAC2) on a 7900 HT Sequence Detection System (ABI). CYBA and NCF4 transcript numbers were quantified absolutely using plasmids that contained the fulllength cDNA of the genes of interest as external standards and normalized to TBP as housekeeping gene. RAC2 mRNA levels were quantified relatively and normalized to TBP.
Statistics
A power calculation before the study was performed based on mean and standard error published for CYBA 242C4T activity effect. 20 This report indicated a substantial difference of CC þ CT carriers compared with TT subjects, resulting in an effect size of 0.63 (mean values of the two groups subtracted and then divided by the global s.d.). We calculated for 10 individuals with TT genotype to detect statistically significant differences with an error rate of 5% and a power of 80%. Considering T-allele frequency of 34.7%, a total number of 83 randomly recruited individuals was envisaged.
Inter-individual variability was estimated using univariate ANOVA. Phenotypic parameters were assessed for normal distribution (by Shapiro-Wilk test, Q-Q plot analysis and visual inspection of histograms). Since usually RNA concentrations and mostly enzyme activities deviated significantly from normal distribution, ordinal testing was preferred throughout the analysis, that is correlations among phenotypes using Spearman's rank correlation r and associations with genotypes by Kruskal-Wallis test and Jonckheere-Terpstra test for investigation of an allele dosage trend. Hardy-Weinberg equilibrium of genotypes was verified using a w 2 goodness-of-fit test and no violation was observed at error level of 5%. For combined analyses and to allow for adjustments of possibly confounding factors, linear regression models were applied. Therefore, to achieve variance homogeneity of the residuals, log-transformed data were used. Correction for multiple testing of five polymorphisms was addressed by the conservative Bonferroni adjustment setting the level of significance at 0.01. All these statistical procedures were carried out with SPSS (version 12.0, Chicago, USA).
